FORNARI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 2.026
EU - Europa 1.516
AS - Asia 700
AF - Africa 75
Continente sconosciuto - Info sul continente non disponibili 17
SA - Sud America 3
Totale 4.337
Nazione #
US - Stati Uniti d'America 2.020
IT - Italia 386
GB - Regno Unito 314
CN - Cina 253
SG - Singapore 231
SE - Svezia 202
DE - Germania 170
IN - India 100
IE - Irlanda 73
CH - Svizzera 70
VN - Vietnam 54
UA - Ucraina 53
FR - Francia 51
BG - Bulgaria 50
RU - Federazione Russa 46
FI - Finlandia 33
EE - Estonia 25
TG - Togo 25
ZA - Sudafrica 23
ID - Indonesia 21
JO - Giordania 17
EU - Europa 15
CI - Costa d'Avorio 12
BE - Belgio 9
HR - Croazia 9
NL - Olanda 8
CA - Canada 6
IL - Israele 5
SC - Seychelles 5
DZ - Algeria 4
GR - Grecia 4
PK - Pakistan 4
AT - Austria 3
NG - Nigeria 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CZ - Repubblica Ceca 2
JP - Giappone 2
KZ - Kazakistan 2
PL - Polonia 2
TH - Thailandia 2
TN - Tunisia 2
BD - Bangladesh 1
BR - Brasile 1
DK - Danimarca 1
EG - Egitto 1
ES - Italia 1
IR - Iran 1
KG - Kirghizistan 1
KR - Corea 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
RO - Romania 1
SI - Slovenia 1
TR - Turchia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 4.337
Città #
Southend 285
Fairfield 257
Singapore 205
Chandler 184
Ashburn 165
Woodbridge 135
Bologna 122
Seattle 117
Houston 115
Wilmington 109
Ann Arbor 95
Santa Clara 82
Princeton 78
Dublin 73
Bern 68
Cambridge 64
Boardman 59
Sofia 50
Dong Ket 35
Helsinki 31
Jacksonville 30
Nanjing 29
Padova 29
Westminster 27
Lomé 25
San Diego 23
Jinan 20
Beijing 19
Jakarta 19
Milan 19
Berlin 18
Amman 17
Los Angeles 15
New York 15
Saint Petersburg 15
Hebei 14
Nanchang 14
Florence 13
Abidjan 12
Turin 12
Zhengzhou 12
Pune 10
Shenyang 10
Brussels 9
Mülheim 9
Falls Church 8
Forlì 8
London 8
Taizhou 8
Bremen 7
Bühl 7
Changsha 7
Des Moines 7
Jiaxing 7
Redmond 7
Verona 7
Amsterdam 6
Dearborn 6
Guangzhou 6
San Giorgio di Piano 6
Chicago 5
Holon 5
Olalla 5
Toronto 5
Xi'an 5
Chengdu 4
Dallas 4
Hyderabad 4
Mahé 4
Medolla 4
Norwalk 4
Philadelphia 4
Tianjin 4
Treviso 4
Wenzhou 4
Abeokuta 3
Bari 3
Boydton 3
Frankfurt Am Main 3
Haikou 3
Hangzhou 3
L’Aquila 3
Medford 3
Munich 3
Ningbo 3
Paris 3
Peshawar 3
Prineville 3
Rome 3
Russi 3
San Lazzaro di Savena 3
Serio 3
Shanghai 3
Shenzhen 3
Wuhan 3
Almaty 2
Athens 2
Beverwijk 2
Brno 2
Busto Arsizio 2
Totale 3.004
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 203
Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate 163
LncRNAs as novel players in hepatocellular carcinoma recurrence 148
CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. 146
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 139
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 135
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 134
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 133
Oncogenic role of miR-483-3p at the IGF2/483 locus. 127
The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma 122
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 118
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 118
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 117
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 116
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 112
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model 111
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. 109
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 107
Design, Synthesis and Biological Evaluation of Pyrazole derivatives as Potential multikinase Inhibitors in Hepatocarcinoma. 106
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 106
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 104
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 103
MicroRNAs in Animal Models of HCC 102
null 101
MicroRNA involvement in hepatocellular carcinoma. 100
TP53/MicroRNA interplay in hepatocellular carcinoma 95
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 90
The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1 alpha Activity by Changing miR Expression Patterns in Human Cancer Cells 86
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 84
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 83
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 79
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 79
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 76
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 72
Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate 63
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 61
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming 49
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 48
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 46
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 43
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 42
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 41
Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus 40
Animal models of hepatocellular carcinoma prevention 38
Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC 35
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 33
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 32
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic cencerogenesis 28
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 24
MicroRNA and hepatocellular carcinoma: biology and prognostic significance 23
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 23
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much s missing? 16
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 11
Totale 4.520
Categoria #
all - tutte 13.558
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.558


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020745 0 0 0 0 93 106 124 129 126 70 52 45
2020/2021501 92 31 19 16 12 45 34 37 54 39 23 99
2021/2022853 45 20 44 75 60 39 12 120 28 82 215 113
2022/2023936 90 95 56 103 52 78 23 55 164 27 72 121
2023/2024375 40 51 12 47 41 80 8 17 12 27 13 27
2024/2025631 79 211 126 101 114 0 0 0 0 0 0 0
Totale 4.520